Thank you for submitting your manuscript for consideration by The EMBO Journal. I would like to apologize for the fact that it has taken us somewhat longer than usual to evaluate it, but we have now finally received all three sets of reviews on your study, with the comments directly to the authors copied below. As you will see, the referees find your results on dynein regulation by Ndel1 palmitoylation potentially interesting and important, and therefore in principle suited for publication in The EMBO Journal. On the other hand, it is also apparent that the reviewers remain unconvinced that your present set of experiments has provided sufficiently strong support for the main conclusions at this stage. These concerns, detailed most explicitly by reviewer 2 but also mirrored in the comments of the other two referees, pertain mostly to the palmitoylation analyses. I prefer not to go through all the individual concerns here, but I am afraid we feel that they currently preclude publication of the study, at least in its present form.
Given the interest and potential importance of your findings and the topic, I would nevertheless be inclined to give you a chance to respond to the points raised in a revised version of the manuscriptas it is apparent that the study might become a much stronger candidate for The EMBO Journal upon heeding the detailed comments and suggestions of the referees. I do realize that this may require a considerable amount of additional time and effort and may also be technically challenging, and I hope you understand that given the uncertain outcome of such further investigation, I am currently not in a position to predict whether the ultimate decision on acceptance or rejection of your study would be a positive one. However, should you feel confident that you might be able to address the key criticisms and to convince the critical referees, we should be happy to consider a revised manuscript further for publication. In this respect, please bear in mind that it is EMBO Journal policy to allow a single round of major revision only, and that it is therefore essential that you answer to all the points raised at this stage if you wish the manuscript ultimately to be accepted. In any case, please do not hesitate to get back to us should you need feedback on any issue regarding your revision.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal
REFEREE REPORTS -----------------------------------------------------
Referee #1 (Remarks to the Author):
Ndel1 Palmitoylation: a Novel Mean to Regulate Cytoplasmic Dynein Activity Anat Shmueli et al.
Lissencephaly is a devastating brain malformation characterized by smooth cerebral surface and disorganized cortical layers due to defective neuronal migration. Series of reports indicate that the mutated gene, LIS1 is a regulator of cytoplasmic dynein. This pathway is highly conserved among species from yeast to mammals.
This manuscript from Anat Shmueli et al reported the novel modification of NDEL1 by palmitoylation. This work builds toward a novel and interesting model for the regulation of dynein, which is an important unanswered question. Many of the experiments described in this manuscript are clear and some are compelling. However, there are several gaps and unanswered questions that must be addressed.
Of these questions, the most significant are:
(1) Authors claimed that palmitoylation of NDEL1 is an important for proper regulation of dynein through RNAi or overexpression of wild type or mutated NDEL1. To verify this conclusion, they should quantitate how much population of endogenous NDEL1 is palmitoylated. Because, if small fraction of NDEL1 is only palmitoylated, their conclusion could become different.
(2) We are told that palmitoylation of NDEL1 reduces the affinity with dynein. The data are plausible but indirect. They should proof this notion by further biochemical analysis such as motility assay.
(3) They argued that DHHC7 is a major contributor regarding neuronal migration. On the other hand DHHC7 is mainly expressed cortical layer. Cortical layer is occupied by post-migrated neurons. I think they should provide some explanations. In this series, I am curious whether KD of DHHC7 is rescued by expression of DHHC2 or DHHC3.
Additional specific points:
(1) They presented in vitro palmitoylation assay in figure 1. However, palmitoylation of NDE1 by DHHC2 is not clear.
(2) Figure 1C is confusing. I can not connect the panels and the explanation in the text.
(3) Figure 3B : reduction of NDEL1 after palmitate treatment is not clear to me.
(4) Discussion regarding the difference of mutation effect on NDEL1 and NDE1 is not sufficient. It should be beefed up.
(5) They examined the effect of mutant expression on organelle distribution. They should also present the effect on LIS1 or dynein localization. Because it is more direct effect.
Overall, this manuscript has significant potential to make a contribution, but there are several issues that must be addressed for this work to have real impact in the field.
Referee #2 (Remarks to the Author):
In this report, the authors show that the two paralogous dynein motor accessory proteins, Nde1 and Ndel1, are palmitoylated and provide intriguing data indicating that palmitoylation Ndel1, but not Nde1, plays a key role in modulating dynein function. Using the now standard Fukata/Bredt approach of co-transfecting palmitoylation substrate proteins individually with the full panel of 23 DHHC palmitoylation enzymes, they find that a subset of three enzymes, i.e. DHHC2, DHHC3, and DHHC7, have specificity for Nde1 and Ndel1. Furthermore, mutation of a single cysteine residue, C273S, is found to abolish palmitoylation of both proteins, implicating this cysteine as the sole palmitoyl-acceptor in both proteins. With a number of different approaches, the authors present data indicating that up-regulation of Ndel1 palmitoylation inhibits dynein function, leading to a model in Ndel1 palmitoylation regulates dynein motor activity.
The main thesis is that reversible palmitoylation of Ndel1 on Cys273 within the Ndel1 dynein binding domain, regulates Ndel1 interaction with the dynein intermediate chain (DIC) and thereby, dynein motor activity. The palmitoylation serves to block interaction with DIC. An unusual feature of their model is that rather than modulating membrane interaction, as is typical for palmitoylregulation, they believe that the fat addition within this domain directly disrupts its binding functionality.
Potentially, this is a very interesting finding with far-reaching consequences for cell biology. Unfortunately, I find that there are major problems with the manuscript in its current presentation. It is quite poorly documented and I feel that there are multiple problems with many of the experiments supporting their conclusions. Consequently, I do not have high level of confidence in the manuscript's conclusions.
First, a couple of general points: 1. Regulation of dynein function by Ndel1 palmitoylation. Many of the results implicating Ndel1 palmitoylation in regulating dynein are indirect with the dynein effects potentially being mediated by processes other than by actions on Ndel1 palmitoylation. For instance, 2-bromopalmitate (2BP), a poorly characterized, generalized inhibitor of protein palmitoylation, which is widely used throughout this report, is expected to inhibit all palmitoylation within the cell, not just Ndel1 palmitoylation. Furthermore, 2BP also inhibits many other enzymes that have nothing to do with palmitoylation. Its effects on dynein function could well be exerted indirectly. Likewise, the same can be said for the approaches overproducing or knocking down the individual DHHC proteins; each of these also are expect to impact multiple palmitoylation substrate proteins. The most specific reagent used here, is the Ndel1(C273S) palmitoylation site mutant. Indeed, the most convincing expts are the ones employing DHHC7 overproduction together with either wild-type Ndel1 and the Ndel1(C273S) mutant. However, here too, there are concerns (see #2 below).
2. Ndel1 palmitoylation site. Unfortunately, short of direct structural analysis, there is no good way of determining the sites of a protein's palmitoylation. Here, the authors take the standard approach of individually mutating each cysteine. These results indicate Cys273 to be the sole palmitoylaccepting residue in both Nde1 and Ndel1. The concern with this sort of approach is the possibility that the palmitoylation blocking effects may be exerted indirectly. As Cys273 maps within the Ndel1 dynein binding domain, a plausible possibility is that the obligate substrate for palmitoylation is a complex of Ndel1 with its accessory dynein subunits. Thus, C273S could block palmitoylation by blocking complex formation; the actual palmitoylation site could well be far removed, on distant cysteine(s). Indeed, they find that the C273S mutation when introduced into the homologous binding site of the paralogous Nde1 quite clearly has palmitoylation-independent consequences (Fig. 3E) ; this certainly adds plausibility to this type of alternative explanation.
2b. It is also worth noting that the Cys273 context does not look particularly much like a palmitoylation site. Palmitoylation often occurs on clustered cysteines, or on cysteines proximal to polybasic domains, transmembrane domains or other lipidation sites. This sequence has none of these features. Nonetheless, this certainly does not rule out this site, since palmitoylation can occur in a wide variety of sequence contexts, and the "rules" specifying palmitoylation are not yet defined.
Major points: 3. I was very frustrated by the very incomplete nature of the Methods provided. In many cases, it was difficult or impossible to discern the details of what was done experimentally either from the Methods or from the figure legends. Major details were missing for virtually every experiment. Generally, I am not a stickler for this and I am happy with shorthand descriptions for widely used technologies. Many of the techniques used here, however, are not typical. A detailed Methods section should be included as part of the online supplement. Below, I have listed a few examples of things that were omitted: 3a. Methods for SFig 1 -lysate preparation, buffers, centrifugal conditions. 3b. A more complete description of the ABE methodology used as it appears that the methods utilized differ substantially from the Drisdel/Green reference given. 3c. Details of the in vitro palmitoylation systems developed in Figs 3B and C -lysate preparations, buffers, etc. 3d. Description of the Flp-In-Ha-DHHC7 allele and conditions for induction. 3e. DN-DHHC7. What is the nature of this dominant-negative mutant? No reference is given. 3f. The VSV-G ER export assay. It appears that temperature-sensitive VSV-G mutant protein defective for ER export is being used. No detail is provided. 3g. Inadequate descriptions of quantitative morphometric methods used.
4. Based on SFig 1, the authors conclude that the Ndel1 palmitoylation effects on dynein function are not mediated through a modulation of membrane localization: "Ndel1 palmitoylation did not grossly increase its relative proportion in the membrane as the relative proportion of wild-type or C273S Ndel1 in the membrane or in the cytosol did not change following expression of the palmitoylation enzyme." My problem with this membrane/cytosol fractionation is that it is reported to have been performed in the presence of 0.5% Triton X-100, a condition under which membranes would be expected to be largely dissolved by the detergent. One might expect membrane proteins as well as proteins that tether to membranes through lipid modifications to be extracted to the supernatant under these conditions. Indeed, it is surprising under these conditions that DHHC7-membrane interaction survives the detergent treatment and fractionates so cleanly to the pellet fraction. What is the rationale for including detergent in this fractionation? Perhaps their reporting of the use of Triton is an error? Bottomlime -one cannot conclude from this expt that palmitoylation does not increase Ndel1 fractionation to membranes. 4b. Indeed, my inspection of Figs. 4 and 5, suggests that Ndel1 palmitoylation may promote localization to membranes. In Fig. 4 , peri-Golgi fluorescence is seen for Ndel1(wt), but not for Ndel1(C273S). Likewise in Fig. 5 , a substantial peri-surface fluorescence is evident for the Ndel1(wt). This deserves comment. 5. Fig. 1G and H. Half-life of Ndel1 palmitoylation. I also have concerns regarding this determination of a 2.3 h half-life for the Ndel1 palmitoyl-modifications. My understanding (although again, the provided methodological details are quite sketchy) is that this expt involves a multi-day ABE processing of each of the timepoints through multiple chemical treatments. I am concerned about how quantitative this data is. In fact, there does look to be considerable sample-tosample variation in the amount of Ndel1 protein detected per sample (Fig. 3G, lower panel) . 6. I have major concerns relating to experiments of Figs. 3B and C. 6a. Fig. 3B . Based on the limited detail provided, my understanding is that this expt involves an atypical in vitro use of 2BP. In a crude in vitro system, a lysate from P7 brain, 2BP is found to enhance the co-IP of DIC with Ndel1. 2BP is presumed to block an ongoing palmitoylation of Ndel1 in this in vitro system, facilitating thereby, an Ndel1-DIC interaction. My main problem is with the presumption of ongoing in vitro palmitoylation. In vitro palmitoylation systems have been notoriously difficult to faithfully set up (which largely explains the 20-year lag prior to the first palmitoyl-transferase enzyme identifications). Are the authors certain that faithful, bona fide Ndel1 palmitoylation is occurring in these lysates? No details regarding the lysate preparation or the in vitro system are provided. Furthermore, as mentioned above, 2BP is well known for its diverse nonspecific actions and the 2BP effects could well be exerted indirectly. 6b. Fig. 3C . This is another biochemically complex expt that, like Fig 3B also assumes ongoing in vitro palmitoylation. Many of the concerns voiced above for Fig. 3B also apply here. It appears here (again, experimental detail is quite sparse) that this expt involves mixing lysates from P2 brains with lysates from cells expressing or not expressing DHHC7 from a Tet-inducible promoter. To these mixed lysates, purified GST-Ndel1 fusion proteins (purified from E. coli?) are added. The ability of Ndel1 to co-IP DIC is interpreted as being modulated by an in vitro palmitoylation of Ndel1 by DHHC7. The lower Fig 3C panel (not described within the legend), I believe, is intended to provide evidence that such in vitro palmitoylation is occurring. If so, it is deficient in that it fails to show a reliance of this in vitro palmitoylation on the induced presence of the DHHC7 in the lysate.
Overall, I find that these two expts (Figs. 3B and C) to be not very believable.
7. Many of their conclusions rely on effects of DHHC7 being co-overproduced together with either wild-type Ndel1 or the Ndel1(C273S) mutant (Figs. 3D, 4, 5, 6, and 7) . In each case, inhibition of dynein function is seen for the DHHC7 + Ndel1(wt) condition, but not for the DHHC7 + Ndel(C273S) condition. This reliance on overproduction limits conclusions. The overproduced, palmitoylated Ndel1 appears to be acting as a dominant negative poison of the dynein machine. Is this an overproduction artifact? Or, does it reflect, as the authors believe, an endogenous mechanism which normally serves to regulate dynein function? It is important to show that this palmitoylregulatory mechanism also applies to endogenous Ndel1. Unfortunately, it is difficult to fully address this experimentally. One approach that should prove somewhat enlightening is to examine the effects of DHHC7 overproduction in the absence of Ndel1 overproduction. Does uppalmitoylation of endogenous Ndel1 inhibit dynein function? This appears to have been examined in Fig. 4 and 7. Unfortunately, the two expts give contradictory results. In Fig. 4 , there appears to no effect of DHHC7 overproduction by itself -i.e. no indication that up-palmitoylation of endogenous Ndel is inhibitory. In contrast, Fig. 7G -L provides some evidence for such an endogenous regulatory mechanism, with overproduction of DN-DHHC7 skewing endogenous Ndel1 localization more towards the cell body, consistent with a disinhibition of dynein function. What is the explanation for this discrepancy?
8. The results of Figs. 5 and 6 are fairly subtle and do not provide much strong support for their model. 9. Another deficiency is the authors' failure to track Ndel1 palmitoylation in any of the key expts, e.g. Figs. 4, 5, 6, and 7 . Do conditions that perturb dynein function, e.g. 2BP, DHHC7, or DN-DHHC7 overproduction, result in the expected changes in Ndel1 palmitoylation? Although this is difficult, it should be possible for expts with cells having relatively high transfection efficiencies, e.g. the NIH3T3 cells of Fig. 4 .
Other comments: 10. The figure legends contain a great deal of results discussion and interpretion which should be in the Results section.
11. The 3C section of the Fig 3 legend ends with two sentences that appear to be out of place. "In the bottom row the input recombinant Ndel1 is shown by Western blot on the left side, two bands are evident, the upper probably due to phosphorylation. On the right the presence of DHHC3 and DHHC7 in the brain lysate is shown by Western blot."
12. DIC and Dynein ICH are used interchangeably in the Figures and text. This is confusing. Please pick one and stick with it.
13. Fig. 3D . What amount of input lysate control is blotted relatively to the amount of IP sample blotted? For instance, is it correct to conclude that 100% of the endogenous Lis1 and perhaps 50% of DIC can be pulled down with GFP-Ndel1? 14. Fig. 7 -changes in neuritic distribution of Lis1 and Ndel1. The strategy for quantitating these changes in distribution (relative fluorescence intensity at neurite tip vs cell body) does not seem particularly illuminating. Perhaps it would be better to somehow represent the linear distribution of fluorescence along the neurite length? distance from cell body?
Referee #3 (Remarks to the Author):
The manuscript by Shmeuli et al.investigates the palmitoylation of Ndel1, which associates with Lis1 and is thought to regulate cytoplasmic dynein. The authors demonstrate that both Ndel1 and its homolog Nde1 can be palmitoylated in the cell, and identify a conserved cys residue as a primary site for modification. The interaction of Ndel1 and dynein is reported to be sensitive to palmitoylation. Further, palmitoylated Nde1 is reported to inhibit dynein activity in cellular assays. This work therefore suggests a novel regulatory mechanism for dynein.
This work is novel and potentially offers significant insight into dynein regulation in the cell. The work is through, well-performed, and well-controlled. This work merits publication in a strong journal, pending some minor revisions.
1. Both the introduction and the discussion sections could be tightened to improve clarity. For example, the discussion of the effects of Lis1 and Ndel1 on dynein activity in the introduction is insufficient, and will be confusing to most readers. Also, in the discussion section, the "autoregulatory features built" into dynein are not clear to me -the authors should clarify. 2. The palmitoylation-induced changes in the association of Ndel1 and dynein shown in Fig. 3 should be quantitated more rigorously. 3. The cell images in Fig. 4 are too small and too high contrast. 4. The assay in Fig. 5 is too convoluted to really provide mechanistic insight. This assay should either be removed from the manuscript altogether or at least relegated to the supplemental section. 5. The authors conclude on p. 8 that Ndel1 palmitoylation occurs on a single site. How do they know this? Could it be that palmitoylation of C273 is required for any subsequent modifications? 6. The discussion of the differences in the effects of palmitoylation of either Nde1 or Ndel1 and their association with dynein (p. 9) is confusing. 7. In the experiments in Fig. 4 , why does over-expression of DHHC7 not affect the regulation of the endogenous proteins?
Overall, this is nice work on a novel regulatory mechanism. Estimation of what is the amount of endogenous Ndel1 that undergoes palmitoylation is rather difficult, since the methods that allow visualization of the palmitoylated protein do not visualize the unpalmitoylated protein at the same time.
We have chosen to look at the population of Ndel1 in CAD cells where our experiments suggest that the endogenous protein undergoes significant palmitoylation. We compared the mobility of the protein with or without addition of a high concentration of reducing agent (200 mM DTT). As can be seen in Fig. 1F , the mobility of Ndel1 is faster following addition of the reducing agent, thus suggesting that a significant proportion of the endogenous Ndel1 population undergoes palmitoylation. A similar band shift has been noted for PSD-95 (Fukata et al, 2004 ), which we repeated and is shown here (Fig. 1E) . We noticed such a band shift also for Fyn, which is a palmitoylated protein (Shenoy-Scaria et al, 1994) (Koegl et al, 1994 ) (data not shown). We added to the text "It has been previously demonstrated that a band-shift of PSD95 can be noted following reduction ( (Fukata et al, 2004) , Fig. 1E ). We noted a similar band-shift of Ndel1 (Fig.  1F) , thus suggesting that a noticeable proportion of Ndel1 population is palmitoylated in CAD cells." This issue was approached by directly monitoring the retrograde movements of DIC-mCherry puncta within axons of primary cerebellar neurons. We assume that retrograde movements of dynein puncta within the axon are likely to reflect dynein activity. Our findings indicate that addition of the non-palmitoylated form of Ndel1 increases the processivity of the retrograde tracks in comparison to wild-type Ndel1. An additional section, an additional main figure, a section in the supplementary methods and two supplementary movies were added. Section:
The aforementioned experiments provided us with indirect evidence regarding DIC activity. To monitor DIC activity directly we transfected primary cerebellar neurons with DIC-1B-mCherry and either GFP-Ndel1 or GFP-Ndel1(C273S) and monitored the movements of the fluorescent dynein puncta within the axons (Ha et al, 2008) . DIC puncta were tracked using the Imaris program (supplementary movies 1 and 2 are examples of DIC-mCherry puncta in neurons transfected with GFP-Ndel1 or GFPNdel1( C273S), respectively). In each time frame the position of the puncta were subtracted from the previous time frame and the relative orientation in relation to the cell body was determined ( Fig. 6A-D) . The processivity of DIC-1B-mCherry puncta increased in a significant way when the unpalmitoylatable form of Ndel1(C273S) was present the number of point per track increased to (19.07±0.9, n=280 versus 16.12±0.7, n=314; p=0.0107 (Fig. 6E) . Nevertheless, there was no change in the average retrograde velocity (Fig. 6F ).
Figure legend: Figure 6 : Unpalmitoylated Ndel1 increases the processivity of DIC-mCherry puncta retrograde tracks. Primary cerebellar neurons were transfected with either GFP-Ndel1 wild-type or C273S mutant and DIC-mCherry. The red fluorescent puncta were tracked using Imaris software. A-D) DIC-mCherry puncta were identified and their movements in the axon were tracked. In each time-lapse (here 4 sec intervals are shown), the position of each puncta was compared to its previous position. Arrowheads mark trackable puncta. Retrograde and anterograde motility was defined according to the movement to or from the cell body. E) The number of points in each retrograde track was plotted and the differences between neurons transfected with Ndel1 C273S and Ndel1 were significant p=0.0107. F) Expression of Ndel1 C273S did not change the velocity in the retrograde direction. The addition to the supplementary methods appears as "Tracking DIC-mCherry puncta". We agree that the expression of DHHC7 is higher in the cortical plate. Nevertheless we do see some expression also in other areas of the cortex. The deduced expression pattern maybe somewhat misleading since the interpretation is based on a signal to noise ratio. For example, the expression of Dcx, which plays an important role in neuronal migration, is highly expressed in the cortical plate and the level of expression in the intermediate zone is markedly reduced. We add a figure for the referee illustrating this point (referee figure 1). Legend: In situ hybridization of Dcx and Zdhhc7 in E14.5 embryos. The expression of Dcx (A) is restricted to the central nervous system. In the developing telencephalon the highest level of expression is noted in the cortical plate (CP), see also in the inset. No expression can be detected in the ventricular zone (VZ). The expression of Zdhhc7 is wider spread (B). Within the developing telencephalon higher expression is observed in the CP, but there is a signal also in the VZ. Scale bar for embryo sections 300 m, for insets 50 m. Data was obtained from http://www.genepaint.org/. In this series, I am curious whether KD of DHHC7 is rescued by expression of DHHC2 or DHHC3.
Our experiments suggest that there should be some specificity among the substrates. Expression of DHHC3 did not rescue KD of DHHC7, and expression of DHHC7 did not rescue KD of DHHC2. This information was added to the main text. "In addition, enzyme specificity was explored by trying to rescue knockdown of DHHC7 by DHHC3 or knockdown of DHHC2 by DHHC7. In both cases there was no significant improvement in neuronal migration. "
(1) They presented in vitro palmitoylation assay in figure 1 . However, palmitoylation of NDE1 by DHHC2 is not clear.
We added a supplementary figure of the screen of NDE1 using a longer exposure where NDE1 palmitoylation is more evident. This is supplementary figure S1.
The related section was rephrased. This assay involves an exchange of the endogenous palmitate-linked group with a biotinlabeled reagent. This reaction requires hydroxylamine-mediated cleavage of the palmitoyl-thioester bond, followed by a specific labeling with a sulfhydryl-reactive biotinylated reagent, which is later recognized identified by avidin-HRP (known as ABE, acyl biotin exchange method). Our results indicate that both Ndel1 and Nde1 are palmitoylated in vivo in mouse cortical neurons ( Fig. 1C-D) . In both cases avidin-HRP labeled immunoprecipitated Ndel1 (Fig. 1C) or Nde1 ( Fig. 1D ) only when the palmitoylthioester bond was reduced by hydroxylamine, but not when no reducing agent was added.
The corresponding legend was modified as well. (3) Figure 3B : reduction of NDEL1 after palmitate treatment is not clear to me.
Figure 3 was modified and we believe that the differences are clearer.
(4) Discussion regarding the difference of mutation effect on NDEL1 and NDE1 is not sufficient. It should be beefed up.
We added several additional sentences. "The difference between the behavior of Nde1 and Ndel1 in that respect may be due to slight differences in the sequence of the amino acids surrounding C273. In case of Ndel1 the amino acid in position 272 is alanine, which is a hydrophobic amino acid, whereas in case of Nde1 it is serine, which is an hydrophilic amino acid. Furthermore, the similarity between Ndel1 and Nde1 is markedly reduced after amino acid 277 (25.7% identity versus 54.4% identity along the whole protein). Amino acids in that region may also contribute to the interaction with dynein. Structural analysis of the complexes involving Nde1 or Ndel1 and dynein are likely to provide better insight into this issue."
We have examined the effect of the mutant expression on the intracellular localization of LIS1 in CAD cells. The results are probably clearer now following the new analysis suggested by reviewer #2. Less LIS1 exists in the tip of the neurons in comparison to the cell body when the mutant is expressed. The difference was statistically significant. In addition, we added a section monitoring trafficking of DIC puncta (see response to question 2 above). The related section was rewritten: "Transport to neurite tips The localization of LIS1 and Ndel1 at the tips of neurites is determined by a balance between molecular motors working in different orientations; cytoplasmic dynein and kinesin (Taya et al, 2007) . To test whether palmitoylation of Ndel1 affects the balance between cytoplasmic dynein and kinesin activities, we quantified the relative immunoreactivity fluorescence intensity of Ndel1, LIS1, and Nde1 in the neurite tips of differentiated CAD cells in comparison with the relative immunoreactivity fluorescence intensity found at the connection of the neurite to the cell body. Most differentiated CAD cells exhibited relatively higher intensities of LIS1 and Ndel1 at the neurite tips 57±0.07% (n=49) and 84±0.05% (n=39) respectively (Fig. 5A ,C,I). Addition of the palmitoylation inhibitor 2-Br, significantly reduced the relative localization of LIS1 and Ndel1 at the neurite tips (8.5±3.3% (n=70, p<0.0001) and 62±7.3% (n=45, p=0.02) respectively, Fig. 5B ,D,I). Therefore, as expected, this treatment led to enhanced Ndel1 and LIS1 mobilization in the retrograde direction towards the cell body. In contrast, the localization of Nde1 at the tips was not altered following inhibition of palmitoylation (data not shown).
Overexpression of the dominant-negative form of GFP-DHHC7 significantly reduced the relative position of Ndel1 at the neurite tips, from 51±6.1% (n=68) to 27±6% (n=55, p=0.006) in comparison to overexpression of this enzyme (Fig. 5E ,F,I). In agreement with previous results, the localization of Nde1 was not affected by overexpression of either DHHC7 or DN-DHHC7 (the relative frequency of Nde1 at the tip was 71±7.3% (n=39) versus 55±7.7% (n=42)). Next, we tested the effect of expressing the Ndel1 palmitoylation mutant on the localization of LIS1. In concord with the assays described above, the enhancement of cytoplasmic dynein activity by the palmitoylation mutant led to a reduction of the relative amount of LIS1 localized in the neurite tips in comparison to wild-type Ndel1 (Fig. 5GI ). In these cells, the relative proportion of cells expressing more LIS1 in the tips was decreased in a significant way from 53±7% (n=41) to 23±5% (n=52, p=0.002). Expression of either wild-type or the C273S mutant of Nde1 did not affect LIS1 localization at the tips of neurites in differentiated CAD cells (data not shown). We conclude that Ndel1 palmitoylation leads to reduced dynein activity which may disturb the balance between the activities of the plus and minus end motors, resulting in the accumulation of LIS1 and Ndel1 at neurite tips." The related legend was modified as well " Figure We agree with the reviewer that each single method of manipulation of Ndel1 palmitoylation has its advantages and disadvantages. This is the reason that we have combined several different approaches and since in all of them the same conclusions are reached we believe that the combination of approaches allows us to have a wider basis for our conclusions. As mentioned above the most specific reagent used is the addition of either wild-type Ndel1 or the Ndel1(C273S) mutant. Taking this into consideration, and following the comments of referee #1, we have chosen to monitor directly the movements of DIC-1B-mCherry puncta in the presence of either wild-type Ndel1 or the Ndel1(C273S) mutant. The addition of the unpalmitoylatable Ndel1 mutant significantly changed the processivity of retrograde tracks. Additional sections were added to the results and methods and an additional figure and supplementary movies were added (detailed above in response to reviewer #1 query #2). 2-Bromopalmitate has been widely used by many investigators and its activity has been better characterized recently (Jennings et al, 2009) , it inhibits palmitoyltransferase activity in an irreversible way. 2-Bromopalmitate is the most commonly used inhibitor of palmitoylation. 2-Bromopalmitate inhibits palmitoylation in cells (Webb et al, 2000) and palmitoyltransferase activity of DHHC proteins in vitro (Fukata et al, 2004) . However, it can inhibit additional enzymes as well; it has been found that 2-Bromopalmitate also inhibits fatty acid CoA ligase (Chase & Tubbs, 1972) and other enzymes involved in lipid metabolism (Coleman et al, 1992) . We believe that 2-Bromopalmitate is a useful tool to be applied in palmitoylation studies. We fear that there has been some confusion in the above statement and we would like to better clarify the results. Nde1 is clearly palmitoylated on C273, when the palmitoylation site is mutated, there is no palmitoylation of Nde1. Since Nde1 does not contain alternative cysteines an alternative palmitoylation site cannot be considered. The C273 mutation in Nde1 affects its interaction with dynein in a palmitoylation independent way. However, alternative explanations may exist as indicated by the reviewer. We added to the text: "An alternative explanation will be that this site is required for palmitoylation of other sites. We conclude that both Ndel1 and Nde1 can be palmitoylated in vitro and in vivo by DHHC2, 3, and 7, and C273 is important for palmitoylation." 2b. It is also worth noting that the Cys273 context does not look particularly much like a palmitoylation site. Palmitoylation often occurs on clustered cysteines, or on cysteines proximal to polybasic domains, transmembrane domains or other lipidation sites. This sequence has none of these features. Nonetheless, this certainly does not rule out this site, since palmitoylation can occur in a wide variety of sequence contexts, and the "rules" specifying palmitoylation are not yet defined. We agree with the statement that palmitoylation can occur in a wide variety of sequence contexts. We apologize and hope that the added details are sufficient.
3a. Methods for SFig 1 -lysate preparation, buffers, centrifugal conditions.
This figure was now changed to supplementary Fig. S2 . This following information was added in the supplementary methods. Soluble and Insoluble fractionation Transfected CAD cells grown on 9 cm plates were washed on the plate once with PBS and then with MES buffer (50 mM MES pH 6.8, 2.5 mM EGTA, 2.5 mM MgCl2). The cells were extracted for 3 min with 0.5 ml of 0.5% Triton X-100 in MES buffer supplemented with protease inhibitors. The supernatant (the soluble fraction, cytosol) was collected, centrifuged for 2 min at 16,000 g at 4 o C, and the clear supernatant was then transferred to new tubes. The detergent-insoluble matrix (membrane) remaining on the plate was extracted in 200 l of 2X protein sample buffer without dye, scraped from the plate with rubber policeman and collected into tubes (this is InSol). To the clear supernatant (Sol fraction) two volumes of cold ethanol were added and the tubes were incubated overnight at -20 o C. The Sol fraction was centrifuged for 10 min at 16,000 g at 4 o C and resuspended in 200 l of 2X protein sample buffer without dye. The soluble and the insoluble samples were boiled for 3min and loaded on 12% or 10% SDS-PAGE (equivalent volumes of Sol and InSol were loaded). The percentage of the gel was determined according to the molecular weight of the proteins to be analyzed.
3b. A more complete description of the ABE methodology used as it appears that the methods utilized differ substantially from the Drisdel/Green reference given.
This information was as added in the methods.
Labeling of palmitoylated Ndel1 and Nde1 in cells E15 cortices was dissected and cortical neurons were dissociated into MEM media supplemented with 6% glucose, GlutaMAX, 5% Horse serum, 5% Fetal calf serum, B27, and Gentamycin, or HEK293 cells. Briefly, cells were homogenized in lysis buffer (PBS supplemented with 5mM EDTA, 1% Triton X100, 1mM PMSF, 10 g/ l Aprotinin, 1 g/ l Pepstatin A and 10 g/ l Leupeptin, with 40mM of Ní-Ethylmaleimide (E3876, Sigma)). The cell lysates were passed through a 21 Gauge needle and left for 30 minute on ice. The cell lysates were centrifuged at 4 o C for 15 minutes at 13K rpm. The cleared supernatants were transferred to a new eppendorf tubes and then the tubes were rotated at 4 o C overnight. Proteins were then immunoprecipiated with specific antibodies using A/G beads, following IP an additional blocking was conducted by incubating the beads for 1 hr at R.T. in PBS supplemented with 40mM of Ní-Ethylmaleimide. The beads were then washed with PBS and then palmitate was removed by addition of 1M Hydroxylamine pH 7.5 (55458, Fluka), whereas the control was incubated with PBS for 1 hr at R.T. Following this incubation the beads were washed three times in PBS and then incubated with 320 M EZ-Linkô BMCC-Biotin (21900, PIERCE). Proteins were separated by SDS-PAGE and blotted with ExtrAvidinAE-peroxidase (E2886, Sigma) or reacted with specific antibodies.
An additional method of metabolic labeling was added. Details were added in the supplementary data. Metabolic labeling, Click Chemistry HEK293 Ha-DHHC7 cell line was grown as described above. The metabolic labeling and click chemistry was done according to (Charron et al, 2009; Martin & Cravatt, 2009 ). Briefly, 17-octadecynoic acid (BioMol) was dissolved in DMSO to make a 25 mM (1000x) stock, it was diluted in media and briefly sonicated, then added to a confluent 10 cm plate of cells. Cells were labeled overnight. Following metabolic labeling, cells were harvested, washed once with ice-cold phosphate buffered saline (PBS) and pelleted at 1000g for 5 min. Cells were directly lysed in IP buffer; 0.2 ml 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5mM EDTA, 1% Triton-X100 (Sigma) plus protease inhibitors and then incubated for 0.5 hour on ice. Cell lysates were collected after centrifuging at 15000g for 15 min at 4 o C to remove cell debris. A 24 l sample was taken for lysate control. Ndel1 was immunoprecipiated using rabbit polyclonal anti-Ndel1 antibodies linked to affigel beads (in 0.1M HEPES buffer pH 7.9 BioRad). The immunoprecipitated proteins were reacted with 40 L freshly premixed click chemistry reaction cocktail Alexa FlourAE 647 azide or Tetramethylrhodamine azide (Invitrogen) (100 M, 10 mM stock solution in DMSO), Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) (1 mM, 50 mM freshly prepared stock solution in deionized water), Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl methyl] amine (TBTA) (100uM, 1.7 mM stock solution in DMSO) and CuSO4 ∑5H2O (1 mM, 50 mM freshly prepared stock solution in deionized water)] in PBS for 1 hr at room temperature. The reactions were terminated by the addition of 10 L 5◊ reducing SDS-loading buffer with low concentration of DTT (40% glycerol, 200 mM Tris-HCl pH 6.8, 8% SDS, 0.4% bromophenol blue, 20 mM DTT) and heated for 5 min at 95 o C; 25 l was loaded per gel lane for the in-gel fluorescence, and 10 l was loaded per gel lane for Western blot the gels were separated by SDS-PAGE (8% PAGE gel). In-gel Fluorescence Scanning. Proteins separated by SDS-PAGE were visualized by first soaking the gel in 40% Methanol, 10% acetic acid with shaking for 5 min, followed by soaking in deionized water with shaking for 5 min and directly scanning the gel on an Amersham Biosciences Typhoon 9400 variable mode imager (excitation 555 nm, emission 580 nm filter) and Amersham Biosciences Storm imager (excitation 635 nm, emission 650 nm filter). Hydroxylamine Treatment of Gels. After in gel fluorescence, the gels were treated with 40% Methanol, 10% acetic acid with shaking for 6 hr, washed with deionized water (2 ◊ 5 min) was then soaked in PBS, shaking 1 h at room temperature, followed by soaking in 1 M NH2OH (pH 7.4), shaking overnight at room temperature, The gel was washed with deionized water (2 ◊ 5 min) and scanned for the post-hydroxylamine treatment fluorescence. Immunoblotting. Proteins separated by SDS-PAGE were transferred (50 mM Tris, 40 mM glycine, 0.0375% SDS, 20% Methanol in deionized water, Bio-Rad Trans-Blotter 100 V, 1 h) onto a nitrocellulose membrane. The membrane was blocked (5% nonfat dried milk, and 0.1% Tween-20 in PBS, PBS-T) for 1 h at room temperature. The membrane was washed twice with PBS-T, incubated with the different antibodies at recommended concentrations in PBST with rat anti-Ndel1 monoclonal (1:150), or mouse anti-GFP monoclonal (1:1000, Roche), respectively, followed by a goat anti-the primary origin-HRP conjugated secondary antibody (Santa Cruz) in the blocking buffer with streptavidin-horseradish peroxidase (1 mg/mL diluted 1:25,000 in PBST, Pierce), and subsequently developed with ECL Western blotting detection reagents (Amersham). Figs 3B and C -lysate preparations, buffers, etc. We removed the in vitro palmitoylation results.
3c. Details of the in vitro palmitoylation systems developed in

3d. Description of the Flp-In-Ha-DHHC7 allele and conditions for induction.
We added additional sections to the supplementary methods. Plasmid generation: pcDNA5 FRT-Ha-DHHC7 was generated by ligating the vector and the insert. The vector, pcDNA5 FRT was digested with BamHI and with NotI. The insert, Hatagged DHHC7, was digested with BglII and NotI. The Flp-In vector pcDNA5 FRT-Ha-DHHC7 was transfected to the Flp-Inô TREx ô-293 cell line described above together with the Flp recombinase vector. Cells were grown as described for HEK293 cells with the exceptions that a special Fetal Bovine Serum not containing tetracycline (Tetracycline Screened Fetal Bovine Serum, HyClone, USA) with the additional antibiotics used for selection (hygromycin B 100 g/ml, blastcidin S 15 g/ml (both from InvivoGen, San Diego, CA)) were added. To induce expression, tetracycline 10 g/ml (Cell culture grade, Sigma, Rehovot, Israel) was added to the media. The expression of the induced Hatagged protein was verified by Western blot analysis at specific time points following induction in comparison to uninduced cells. The earliest expression of the Ha-tagged protein was noted eight hours after tetracycline addition.
3e. DN-DHHC7. What is the nature of this dominant-negative mutant? No reference is given.
Expression of the dominant-negative C159S mutant of DHHC2/15 was described in Fukata et al, Neuron 2004 (Fukata et al, 2004 . The dominant-negative C157S mutant of DHHC3/GODZ has been described in (Fang et al, 2006) . In that manuscript, they also demonstrated that overexpressed, enzymatically inactive GODZC157S can multimerize and interact with GODZ and its paralog SERZ-fl. This finding provides a rationale for dominant-negative activity of Cys-Alasubstituted DHHC proteins. We added an additional sentence to the supplementary methods: "Previously it was reported that catalytically inactive DHHS3 forms multimers with wild type DHHC3 and DHHC7, and functions as a dominant negative mutant (Fang et al, 2006) . By analogy, catalytically inactive DHHS7 (C160S) used in this study, functions as a dominant negative mutant."
3f. The VSV-G ER export assay. It appears that temperature-sensitive VSV-G mutant protein defective for ER export is being used. No detail is provided.
Perhaps some of the included details were not noted (see below). Nevertheless, in order to further clarify our experiments we have expanded the related section in the supplementary methods. 1. The abstract mentions "transport of temperature sensitive VSVG". The main text includes a few sentences "Dynein-mediated VSVG transport The viral glycoprotein VSVG is synthesized in the ER and then transported onwards towards the Golgi complex along microtubules by using the activity of the retrograde motor cytoplasmic dynein (Presley et al, 1997) . It has been reported that the temperature sensitive fluorescent VSVG is rapidly translocated into the Golgi region following a 40 0 C to 32 0 C temperature shift. Activation of cytoplasmic dynein is expected to result in a compact fluorescent VSVG localization during a shorter time period." In addition, there was an explanation in the methods part. 3. We added additional details in the supplementary methods. Trafficking of VSV-G protein: COS7 cells were transfected with temperature-sensitive ts045 VSVG-mCherry (Wehland et al, 1982; Arnheiter et al, 1984; Kreis & Lodish, 1986; Bergmann, 1989; Presley et al, 1997 ) and Ha-tagged DHHC7 along with either GFP-Ndel1 or GFPC273S-Ndel1 and incubated at the nonpermissive temperature of 40 o C for 24 h. Cells were next shifted to the permissive temperature of 32 o C, incubated for up to thirty minutes and fixed at five minute intervals. Cells were washed once in PBS, fixed with 4% paraformaldehyde, and processed for immunofluorescence. VSVGmCherry and GFP tagged Ndel1 proteins were visualized using Epi-Fluorescence, Ha-tagged DHHC7 was visualized by immunostaining using antibodies to HA and secondary fluorescent antibodies.
3g. Inadequate descriptions of quantitative morphometric methods used.
We added the following sections in the supplementary methods Image Analysis and quantification For quantification purposes all samples within each experiment were collected using the same magnification and microscopy setting. All cells were visualized under the Applied Precision DeltaVision microscopy using a 60X objective. The freeware ImageJ 1.38x by Wayne Rasband was used for image quantification and analysis unless otherwise indicated. Half-life determination In gel fluorescent bands or chemiluminescenceís bands were quantified using ImageJ. Band intensity was determined using the Gel plug-in of that program. The ratio between the in gel fluorescence signal and the Western blot signal was used for normalization. The bestfit linear line was derived and the half-life was determined as the time where the relative signal is equal to 50% of the initial signal. Golgi Analysis For measurements of the size of the Golgi apparatus immunofluorescence of Mannosidase II (an integral Golgi enzyme) was used. The data acquired in the microscope was exported as TIFF images in grey scale and a region of interest for the Golgi apparatus was defined for each cell. The expression of transfect GFP-tagged Ndel1 or C273S Ndel1 was examined in the appropriate channel. The expression of Ha-tagged DHHC7 was examined by immunostaining using anti-Ha-tag antibodies. The area of the Golgi apparatus measured in pixels was then converted to square m. The results were then subjected to statistical analysis. GraphPad Prism computation program version 4.0 for Macintosh was used for all the statistical analysis. Analysis of variance (ANOVA) and the Tukeyís multiple comparison test was used to examine the differences between the different treatments. Temperature sensitive VSVG trafficking COS7 cells were transfected with temperature-sensitive ts045 VSVG-mCherry (Wehland et al, 1982; Arnheiter et al, 1984; Kreis & Lodish, 1986; Bergmann, 1989; Presley et al, 1997 ) and Ha-tagged DHHC7 along with either GFP-Ndel1 or GFP-C273S-Ndel1 and incubated at the nonpermissive temperature of 40 o C for 24 h. Cells were next shifted to the permissive temperature of 32 o C, incubated for up to thirty minutes and fixed at five minute intervals. Cells were washed once in PBS, fixed with 4% paraformaldehyde, and processed for immunofluorescence. VSVG-mCherry and GFP tagged Ndel1 proteins were visualized using Epi-Fluorescence, Ha-tagged DHHC7 was visualized by immunostaining using antibodies to HA and secondary fluorescent antibodies. For the experiment dealing with VSVG trafficking the fluorescent intensity of a fixed average size Golgi apparatus (based on previous measurements of Golgi size) was generated by installation of a Plugin command to create keyboard shortcuts to a fixed Golgi size. Additional information regarding this command is available at http://rsb.info.nih.gov/ij/developer/macro/macros.html. The area of the whole cells was defined using the fluorescence of the green channel labeled by the GFP transfected constructs. The intensity of the fluorescence of VSVG-mCherry within the area of the fixed average size Golgi and within the area of the whole cell was measured. The ratio between these two intensities were calculated and plotted for each time point. VSVGmCherry is transported to the Golgi over time and the ratio increases. The results in the different time point were plotted and subjected to paired t-test statistical analysis. The differences were extremely significant p=0.0005. Microtubule transport assay analysis Microtubule transport was conducted as described (Shu et al, 2004) . Briefly, COS-7 cells were cotransfected with Ha-tagged DHHC7 and GFP-tagged Ndel1 or Nde1 constructs with lipofectamine 2000 (Invitrogene). Forty-eight hours later, nocodazole (Sigma) was added to the medium at a concentration of 10 g/ml to depolymerize all existing microtubules. Three hours later, cells were washed with DMEM culture medium and recovered for 3 min. Vinblastine (Sigma) was then added to the medium at a concentration of 50 nM for 20 min. Cells were fixed in 4% paraformaldehyde and 0.02% glutaraldehyde, and immunostained with anti-tubulin antibodies (monoclonal antibody clone DM1A, Sigma). To quantify the distribution of the microtubule segments in the cell, images acquired by fluorescent microscopy were exported as TIFF files. The images were analyzed using ImageJ. The cell margin was defined as the area occupied by GFP fluorescence and the area was measured (cell area). The area encompassed by the newly synthesized microtubule fragments (MT area) was defined by the anti-tubulin immunostaining. The ratio between the MT area and the cell area was calculated for each cell and subjected to statistical analysis. Paired Studentís t-test was used to examine the differences between the different treatments. Analysis of intensity of immunofluorescence in neurites of CAD cells Three days differentiated CAD cells were transfected using JetPEIô (Polyplustransfection, NY, USA) transfection reagent with the indicated plasmids. Cells were fixed twenty-four hours after transfections and processed for immunostaining with anti-LIS1 antibodies and/or anti-Ndel1/Nde1 antibodies. Images acquired in the Deltavision microscope were opened using Imaris 6.3.0 software (Bitplane AG, www.bitplane.com). Transfected cells were identified by GFP fluorescence. A line histogram of intensity from the neurite tip (defined as point A in all images) to the point connecting the neurite to the cell body (point B if the neurite was defined as a simple line or point C or above if the neurite was subdivided into several sections) was generated in the measurements points tool of the software and the histograms were exported. When the relative intensity at the tip was higher than the intensity in point connecting the neurite to the cell soma, a score of 1 was given to that neurite. When the relative intensity at the tip was lower than the intensity in point connecting the neurite to the cell soma a score of 0 was given to that neurite. The plotted results were subjected to studentís t-test. Tracking DIC-mCherry puncta Primary cerebellar neurons were prepared, transfected and imaged. Rat-WISTAR pups (P5) were scarified and their cerebella were dissected into PBS supplemented with 0.6% glucose and oxygen. Cerebella were first enzymatically digested by Papain and DNase and further dissociated by pipetting. For isolation of granule cells, neurons were passed through a two-step Percoll gradient. The dense cell fraction at the interphase between the 35 and 60% Percoll phases was collected after centrifugation (2000g without break for 10 min), further cleaned by centrifugation (800g, 5min) together with PBS and subjected to transfection of total 3 g DNA using the AmaxaAE electroporation protocol. Cells were plated on Poly-Lysine ñ and Laminin coated, 35mm glass bottom culture dishes (MaTek corporation) and seeded in Glial MEM medium at 37 o C incubator. After 2hr medium was changed to Granule medium. Then, after 48hr cells supplement with 25mM HEPES, were visualized under the Applied Precision DeltaVision microscopy adjusted to 37 o C. Timelapse frames were taken every 1sec for a total of 1min using a 60X objective and 0.8sec exposure. DIC-IB-mCherry puncta were tracked using the tracking module of Imaris version 6.3 (http://www.bitplane.com). The parameters used for the analysis include that the size of the diameter of the puncta 0.4 m, using Brownian type of movement, the maximum distance was 1.2 m including the possibility of 1 gap. The time-lapse was filtered above a manual threshold, and track duration was filtered above 6 seconds. In case of any visible movements the "correct drift" function was applied. Parameters from the spots statistics were exported to Microsoft Excel files, in addition the relative position in relation to the analyzed axon was noted. The exported parameters included the X and Y positions, velocities in X and in Y. Only distances that were longer than one pixel (0.067 m) were included in the analysis. In each time-lapse the anterograde movements and retrograde movements were separated and the distance covered during 1 second was calculated as the square root of X2+Y2 (using X and Y velocities). The distances of each retrograde time lapse was plotted and subjected to statistical analysis. In order to separate the retrograde tracks from the anterograde tracks the direction of motility was noted (in this case only tracks that were positioned on the X or Y axis were analyzed). The sum of the appropriate directional velocities indicated the relative orientation of a specific track. The number of points for tracks moving in the anterograde direction was plotted and subjected to statistical analysis. Statistical analysis of the results was conducted using GraphPad Prism computation program version 4.0 for Macintosh using Studentís t-test using nonparametric Mann Whitney test.
Based on SFig 1, the authors conclude that the Ndel1 palmitoylation effects on dynein function are not mediated through a modulation of membrane localization: "Ndel1 palmitoylation did not grossly increase its relative proportion in the membrane as the relative proportion of wild-type or C273S Ndel1 in the membrane or in the cytosol did not change following expression of the palmitoylation enzyme." My problem with this membrane/cytosol fractionation is that it is reported to have been performed in the presence of 0.5% Triton X-100, a condition under which membranes would be expected to be largely dissolved by the detergent. One might expect membrane proteins as well as proteins that tether to membranes through lipid modifications to be extracted to the supernatant under these conditions. Indeed, it is surprising under these conditions that DHHC7-membrane interaction survives the detergent treatment and fractionates so cleanly to the pellet fraction. What is the rationale for including detergent in this fractionation? Perhaps their reporting of the use of Triton is an error? Bottomlime -one cannot conclude from this expt that palmitoylation does not increase Ndel1 fractionation to membranes.
We agree that purified Golgi membranes will be dissolved using 0.5% Triton X-100. However, it has been documented that 0.5% Triton X-100 is not sufficient to dissolve the Golgi membrane when intact cells are treated with this detergent. Quite interestingly, this insoluble cell pellet has been used in the past to generate Golgispecific antibodies (Lin & Queally, 1982) . To verify that the Golgi membranes are not solubilized following 0.5% Triton X-100 extraction, the same blot was reacted with anti-Mannosidase II antibodies (a well known Golgi marker). The immunoreactivity was restricted to the pellet. This information was added to the supplementary figure.
4b. Indeed, my inspection of Figs. 4 and 5, suggests that Ndel1 palmitoylation may promote localization to membranes. In Fig. 4, peri-Golgi fluorescence is seen for Ndel1(wt), but not for Ndel1(C273S). Likewise in Fig. 5, a substantial peri-surface fluorescence is evident for the Ndel1(wt). This deserves comment.
We added to the text: Nevertheless, we do not exclude the possibility of fine changes in the interaction of Ndel1 and some membranal subpopulations. In relation to Figure 4 : In addition, a portion of Ndel1 clearly localized to the Golgi (Fig. 4A,C) . In relation to the original Figure 5 (now moved to supplementary figure S6 ): In addition, under these experimental conditions, a substantial peri-surface fluorescence is evident for the Ndel1. (Fig. 3G, lower panel) .
Fig. 1G and H. Half-life of Ndel1 palmitoylation. I also have concerns regarding this determination of a 2.3 h half-life for the Ndel1 palmitoyl-modifications. My understanding (although again, the provided methodological details are quite sketchy) is that this expt involves a multi-day ABE processing of each of the timepoints through multiple chemical treatments. I am concerned about how quantitative this data is. In fact, there does look to be considerable sample-to-sample variation in the amount of Ndel1 protein detected per sample
We have determined the half-life of Ndel1 palmitoylation in HEK293 cells expressing inducible Ha-DHHC7 (Fig. 1G,H) using a different method. The method we used in this case was by metabolic labeling using 17-octadecynoic acid followed by wash and addition of cold palmitic acid. Ndel1 was immunoprecipiated and labeled using CLICK chemistry (details are described in the supplementary data). In this case there was less sample-to-sample variation in the amount of Ndel1 protein detected per sample (Fig. 1G) . The deduced half-life was 1.75 hrs, which is in close agreement with our findings in primary neurons. We believe that a similar finding using different methods and different cells provides additional substantiation to our conclusions. Figs. 3B and C. 6a . Fig. 3B We removed these experiments.
I have major concerns relating to experiments of
6b. Fig. 3C. This is another biochemically complex expt that, like Fig 3B also assumes ongoing in vitro palmitoylation. Many of the concerns voiced above for Fig. 3B also apply here. It appears here (again, experimental detail is quite sparse) that this expt involves mixing lysates from P2 brains with lysates from cells expressing or not expressing DHHC7 from a Tet-inducible promoter. To these mixed lysates, purified GST-Ndel1 fusion proteins (purified from E. coli?) are added. The ability of Ndel1 to co-IP DIC is interpreted as being modulated by an in vitro palmitoylation of Ndel1 by DHHC7. The lower Fig 3C panel (not described within the legend), I believe, is intended to provide evidence that such in vitro palmitoylation is occurring. If so, it is deficient in that it fails to show a reliance of this in vitro palmitoylation on the induced presence of the DHHC7 in the lysate. Overall, I find that these two expts (Figs. 3B and C) to be not very believable.
The experiments relying on in vitro palmitoylation were removed. Fig. 3 was modified and the palmitoylation-induced changes noticed following immunoprecipitation were quantified more rigorously. We found that on average non-palmitoyated Ndel1 interacted 3.5±0.8 fold better with DIC. The difference was statistically significant using unpaired t test with Welchís correction (p=0.0154, n=5). (Figs. 3D, 4, 5, 6, and 7) Fig. 4 and 7 . Unfortunately, the two expts give contradictory results. In Fig. 4 , there appears to no effect of DHHC7 overproduction by itself -i.e 
Many of their conclusions rely on effects of DHHC7 being co-overproduced together with either wild-type Ndel1 or the Ndel1(C273S) mutant
. In each case, inhibition of dynein function is seen for the DHHC7 + Ndel1(wt) condition, but not for the DHHC7 + Ndel(C273S) condition. This reliance on overproduction limits conclusions. The overproduced, palmitoylated Ndel1 appears to be acting as a dominant negative poison of the dynein machine. Is this an overproduction artifact? Or, does it reflect, as the authors believe, an endogenous mechanism which normally serves to regulate dynein function? It is important to show that this palmitoylregulatory mechanism also applies to endogenous Ndel1. Unfortunately, it is difficult to fully address this experimentally. One approach that should prove somewhat enlightening is to examine the effects of DHHC7 overproduction in the absence of Ndel1 overproduction. Does up-palmitoylation of endogenous Ndel1 inhibit dynein function? This appears to have been examined in
. no indication that up-palmitoylation of endogenous Ndel is inhibitory. In contrast, Fig. 7G-L provides some evidence for such an endogenous regulatory mechanism, with overproduction of DN-DHHC7 skewing endogenous Ndel1 localization more towards the cell body, consistent with a disinhibition of dynein function. What is the explanation for this discrepancy?
We found that there is a significant difference in the endogenous levels of Ndel1 expression between the cells used in Fig. 4 (COS7 cells) where the expression of Ndel1 is barely visible and those used in Fig. 7 (CAD cells) (now this is Fig. 5) , which express visible amounts of Ndel1. This major difference in the relative expression underlies the need to express exogenous Ndel1 in COS7 cells in order to visualize the result. To further clarify the relative expression levels of the target proteins in the different cells used in this study, we have conducted a comparative Western blot (supplementary figure S4 ). There are very low levels of expression of Ndel1 in HEK293 cells, COS7 cells and NIH3T3 cells. There are low levels of expression of DHHC7 in HEK293 cells, and NIH3T3 cells. DHHC3 is highly expressed in NIH3T3 cells. We do not have antibodies for DHHC2. We do not know whether the activity of the enzymes is directly correlated with their level of expression. In addition, there is not available information regarding the depalmitoylation enzymes. We added a section in the results "This hypothesis was tested directly by monitoring the activity of cytoplasmic dynein using several cellular assays using different cells. The levels of Ndel1 and the palmitoylation enzymes vary in the different cells (supplementary Fig. S4 ). Ndel1 is highly expressed in the brain and in CAD cells, it is expressed in moderate levels in NIH3T3 cells and very low levels in COS7 cells and HEK293 cells. DHHC7 expression is very low in NIH3T3 cells and HEK293 cells, and is better expressed in CAD, COS7, and brain lysate, whereas DHHC3 is expressed at high levels in NIH3T3 cells. Therefore, in some cases we needed to transfect both Ndel1 and the palmitoylation enzyme to observe an effect. " We added a supplementary method and legend Preparation of cell lysates Confluent 10 cm plates of HEK-293, CAD, differentiated CAD, NIH3T3, or COS7 cells were washed once with ice-cold phosphate buffered saline (PBS) and pelleted at 1000g for 5 min. Cells were directly lysed in IP buffer; 0.2 ml 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5mM EDTA, 1% Triton-X100 (Sigma) plus protease inhibitors and then incubated for 0.5 hour on ice. Cell lysates were collected after centrifuging at 15000g for 15 min at 4 0 C to remove cell debris. Brain lysates from P7 Wistar rat pups were lysed directly in the IP buffer. Similar amounts of protein were separated by SDS-PAGE and subjected to Western blot analysis. The relative amounts of proteins were compared by Ponceau Red staining of the Western blot. Supplementary Figure S4 : Ndel1 and the DHHC3 and DHHC7 palmitoylation enzymes are expressed at different levels in the cells used in this study. Cell lysates were prepared as described in the supplementary methods. Similar amounts of proteins were separated by SDS-PAGE and subject to Western blot analysis with the indicated antibodies.
The results of Figs. 5 and 6 are fairly subtle and do not provide much strong support for their model.
We moved these figures to supplementary data. the key expts, e.g. Figs. 4, 5, 6, and 7. Do conditions that perturb dynein function, e.g. 2BP, DHHC7, result 
Another deficiency is the authors' failure to track Ndel1 palmitoylation in any of
in the expected changes in Ndel1 palmitoylation? Although this is difficult, it should be possible for expts with cells having relatively high transfection efficiencies, e.g. the NIH3T3 cells of Fig. 4.
We added a demonstration of a band shift for endogenous Ndel1 in CAD cells (Fig.  1F) , which as discussed above express sufficient amounts of Ndel1 and demonstrate activity of the endogenous palmitoylation enzymes. We demonstrated a reduction in the palmitoylation of Ndel1 in primary cortical neurons (half-life experiment). In addition, we showed that in transfected HEK293 DHHC7 inducible cell line we can monitor the differences in Ndel1 palmitoylaiton following 2BP, DN-DHHC7/active Ha-DHHC7 and mutant Ndel1 (Fig. 3C,D) .
The figure legends were modified to omit discussions and interpretations. Fig 3 legend Modified to DIC.
The 3C section of the
Fig. 3D. What amount of input lysate control is blotted relatively to the amount of IP sample blotted? For instance, is it correct to conclude that 100% of the endogenous Lis1 and perhaps 50% of DIC can be pulled down with GFP-Ndel1?
The amount of input lysate is about 20% relatively to the amount of IP sample blotted.
Fig. 7 -changes in neuritic distribution of Lis1 and Ndel1. The strategy for quantitating these changes in distribution (relative fluorescence intensity at neurite tip vs cell body) does not seem particularly illuminating. Perhaps it would be better to somehow represent the linear distribution of fluorescence along the neurite length? distance from cell body?
The analysis and the figure were changed according to the suggestions of the reviewers. A detailed text in the supplementary methods describes how this analysis was performed. This is now figure 5. The related section was rewritten: "Transport to neurite tips The localization of LIS1 and Ndel1 at the tips of neurites is determined by a balance between molecular motors working in different orientations; cytoplasmic dynein and kinesin (Taya et al, 2007) . To test whether palmitoylation of Ndel1 affects the balance between cytoplasmic dynein and kinesin activities, we quantified the relative immunoreactivity fluorescence intensity of Ndel1, LIS1, and Nde1 in the neurite tips of differentiated CAD cells in comparison with the relative immunoreactivity fluorescence intensity found at the connection of the neurite to the cell body. Most differentiated CAD cells exhibited relatively higher intensities of LIS1 and Ndel1 at the neurite tips 57±0.07% (n=49) and 84±0.05% (n=39) respectively (Fig. 5A,C,I ). Addition of the palmitoylation inhibitor 2-Br, significantly reduced the relative localization of LIS1 and Ndel1 at the neurite tips (8.5±3.3% (n=70, p<0.0001) and 62±7.3% (n=45, p=0.02) respectively, Fig. 5B,D,I ). Therefore, as expected, this treatment led to enhanced Ndel1 and LIS1 mobilization in the retrograde direction towards the cell body. In contrast, the localization of Nde1 at the tips was not altered following inhibition of palmitoylation (data not shown). Overexpression of the dominant-negative form of GFP-DHHC7 significantly reduced the relative position of Ndel1 at the neurite tips, from 51±6.1% (n=68) to 27±6% (n=55, p=0.006) in comparison to overexpression of this enzyme (Fig. 5E,F,I ). In agreement with previous results, the localization of Nde1 was not affected by overexpression of either DHHC7 or DN-DHHC7 (the relative frequency of Nde1 at the tip was 71±7.3% (n=39) versus 55±7.7% (n=42)). Next, we tested the effect of expressing the Ndel1 palmitoylation mutant on the localization of LIS1. In concord with the assays described above, the enhancement of cytoplasmic dynein activity by the palmitoylation mutant led to a reduction of the relative amount of LIS1 localized in the neurite tips in comparison to wild-type Ndel1 (Fig. 5GI) . In these cells, the relative proportion of cells expressing more LIS1 in the tips was decreased in a significant way from 53±7% (n=41) to 23±5% (n=52, p=0.002). Expression of either wild-type or the C273S mutant of Nde1 did not affect LIS1 localization at the tips of neurites in differentiated CAD cells (data not shown). We conclude that Ndel1 palmitoylation leads to reduced dynein activity which may disturb the balance between the activities of the plus and minus end motors, resulting in the accumulation of LIS1 and Ndel1 at neurite tips. The related legend was modified. " Figure 7 : Ndel1 palmitoylation shifts the cellular localization of LIS1 and Ndel1 towards neurite tips. Below each of the neurite images there is line histogram demonstrating the relative fluorescence intensity of the immunostained protein along the neurite. CAD cells were differentiated into neuronal-like cells by serum starvation. 48 hours later, cells were treated with methanol (as a control) (A,C) or with 7.5 mM 2-Br (B,D) for 3.5 hours and then fixed and stained with anti-LIS1 antibodies (A,B) or antiNdel1 (C,D) . WT or the dominant-negative form of GFP-DHHC7 transfected CAD cells were stained with anti-Ndel1 antibodies (E,F). WT or the C273S mutated form of GFPNdel1 transfected CAD cells were stained with anti-LIS1 antibodies (G,H). The percentage of neurites exhibiting relatively higher intensity of fluorescence at the tip was plotted and subjected to Studentís t-test, significance: * P<0.05, **P<0.01, ***P<0.005."
The manuscript by Shmeuli et al.investigates the palmitoylation of Ndel1, which associates with Lis1 and is thought to regulate cytoplasmic dynein. The authors demonstrate that both Ndel1 and its homolog Nde1 can be palmitoylated in the cell, and identify a conserved cys residue as a primary site for modification. The interaction of Ndel1 and dynein is reported to be sensitive to palmitoylation. Further, palmitoylated
Nde1 is reported to inhibit dynein activity in cellular assays. This work therefore suggests a novel regulatory mechanism for dynein. This work is novel and potentially offers significant insight into dynein regulation in the cell. The work is through, well-performed, and well-controlled. This work merits publication in a strong journal, pending some minor revisions. 1. Both the introduction and the discussion sections could be tightened to improve clarity. For example, the discussion of the effects of Lis1 and Ndel1 on dynein activity in the introduction is insufficient, and will be confusing to most readers. Also, in the discussion section, the "autoregulatory features built" into dynein are not clear to me -the authors should clarify.
The introduction was rewritten (see below). Introduction Regulated activity of the retrograde molecular motor, cytoplasmic dynein, is crucial for multiple biological activities ranging from mitosis to long-range neuronal transport. For example, mice lacking cytoplasmic dynein heavy chain exhibit early embryonic lethality (Harada et al, 1998) , whereas abnormal neuronal transport is a common theme underlying pathogenesis of neurodegenerative diseases (reviews (Bruijn et al, 2004; ChevalierLarsen & Holzbaur, 2006; Reiner et al, 2006; Stokin & Goldstein, 2006) ). Dynein, a large multisubunit complex, is one of the two families of microtubule motor proteins (reviews (Goldstein & Yang, 2000; Vallee et al, 2004) ). All dyneins contain the heavy chain, encoding for the ATPase and motor activities, and accessory subunits including intermediate, light intermediate, and light chains. The activity of dynein is regulated at multiple levels. For example, specific combinations of dynein isoforms may contribute to cargo specificity (Ha et al, 2008) . Additional accessory proteins complexes such as dynacin allows dynein to bind a variety of cargoes, regulates dynein motor activity directly and enhances dynein processivity (reviews (Schroer, 2004; Vallee et al, 2004) ). Finally, accumulating evidence suggest that the LIS1-containing protein complex is also involved in regulating cytoplasmic dynein motor activity. Deletions in the LIS1 gene result in a severe human neuronal migration deficit known as lissencephaly (Reiner et al, 1993; Lo Nigro et al, 1997; Pilz et al, 1998) . Protein dosage in this locus is crucial since both decreased and increased LIS1 protein levels affect brain development both in human and in mice (Reiner et al, 1993; Hirotsune et al, 1998; Cahana et al, 2001; Bi et al, 2009 ). LIS1 has been found to interact with several subunits of dynein and dynactin (Faulkner et al, 2000; Sasaki et al, 2000; Smith et al, 2000; Tai et al, 2002) , as well as with the microtubule plus end binding protein CLIP-170 (Coquelle et al, 2002) , suggesting that it modulates dynein activity in more than one way. LIS1 interacts tightly with the evolutionary conserved NUDE proteins (Efimov & Morris, 2000) . In mammals there are two NUDE homologs; Nde1 and its related paralog Ndel1. Nde1 interacts with LIS1, several centrosomal proteins, and dynein light and intermediate chains (Feng et al, 2000; Feng & Walsh, 2004; Hirohashi et al, 2006a; Hirohashi et al, 2006b; Stehman et al, 2007) . Ndel1 is found in complex with LIS1, and dynein heavy and intermediate chains (Niethammer et al, 2000a; Sasaki et al, 2000) . LIS1, Ndel1 and Nde1 all participate in the dynein-mediated processes of intracellular transport (Liu et al, 2000; Niethammer et al, 2000b; Sasaki et al, 2000; Smith et al, 2000; Liang et al, 2004; Yamada et al, 2008) , mitosis (Faulkner et al, 2000; Yan et al, 2003; Feng & Walsh, 2004; Tsai et al, 2005; Guo et al, 2006; Liang et al, 2007; Stehman et al, 2007; Vergnolle & Taylor, 2007) , and neuronal migration (Hirotsune et al, 1998; Feng et al, 2000; Cahana et al, 2001; Feng & Walsh, 2004; Shu et al, 2004; Sasaki et al, 2005; Tsai et al, 2005; Grabham et al, 2007; Tsai et al, 2007) . These complex biological processes are subject to tight multilevel modes of regulation, in which reversible posttranslational modifications play an important role. For example, phosphorylation of Ndel1 is required for neuronal migration and function (Niethammer et al, 2000b; Toyo-oka et al, 2003; Taya et al, 2007) , as well as for proper cell-cycle progression Mori et al, 2007) . In vitro studies demonstrated that LIS1 can stimulate the ATPase activity of cytoplasmic dynein (Mesngon et al, 2006; Yamada et al, 2008) . Furthermore, LIS1 suppressed the motility of cytoplasmic dynein on microtubules, whereas its interacting protein Ndel1 released the blocking effects of LIS1 (Yamada et al, 2008) . In vivo, injection of anti-LIS1 antibodies inhibited the anterograde transport of dynein to the tips of dorsal root ganlia neurons, thus suggesting that LIS1 may affect the activity of the anterograde motor kinesin in relation to dynein transport (Yamada et al, 2008) . Taking into consideration that reversible post-translational modifications are likely to participate in regulation of dynamic processes we tested whether any of the LIS1/Ndel1/Nde1 proteins undergo palmitoylation. Palmitoylation is a reversible posttranslational modification, which has been shown to play an important role in the regulation of protein trafficking (Linder & Deschenes, 2007) , and in the nervous system (Kang et al, 2008 ) (reviews (Dunphy & Linder, 1998; Resh, 1999; El-Husseini Ael & Bredt, 2002; Washbourne, 2004) ). We found that both Ndel1 and Nde1 undergo palmitoylation on a conserved cysteine residue. We further identified the three palmitoylation enzymes DHHC2, DHHC3 and DHHC7 that are involved in this modification. Palmitoylation of Ndel1 reduced its interaction with cytoplasmic dynein resulting in reduced dynein activity measured by functional assays including Golgi distribution, microtubule transport, ER to Golgi transport, transport to neurite tips, retrograde trafficking of dynein pucta in primary neurons, and aberrant pyramidal neuronal migration to the developing cortex. Our results suggest a novel mode of regulating the activity of the molecular motor, cytoplasmic dynein. In the discussion the sentence related to "autoregulatory features" was revised. Dynein heavy chain has at least two different regions involved in regulation of the ATPase enzymatic activity; the stalk and the C-terminal domain (review (Vallee & Hook, 2006) ). Fig. 3 should be quantitated more rigorously. Fig. 3 was modified and the palmitoylation-induced changes were quantified more rigorously. We found that on average non-palmitoyated Ndel1 interacted 3.5±0.8 fold better with DIC. The difference was statistically significant using unpaired t test with Welchís correction (p=0.0154, n=5). Fig. 4 are too small and too high contrast.
The palmitoylation-induced changes in the association of Ndel1 and dynein shown in
The cell images in
We changed the cell images in Fig. 4 and adjusted the text accordingly. Fig. 5 is too convoluted to really provide mechanistic insight. This assay should either be removed from the manuscript altogether or at least relegated to the supplemental section. Fig. 5 was moved to the supplementary section, supplementary figure S5 .
The assay in
The authors conclude on p. 8 that Ndel1 palmitoylation occurs on a single site. How do they know this? Could it be that palmitoylation of C273 is required for any subsequent modifications?
We modified the conclusion and added in the main text. "An alternative explanation will be that this site is required for palmitoylation of other sites. We conclude that both Ndel1 and Nde1 can be palmitoylated in vitro and in vivo by DHHC2, 3, and 7, and C273 is important for palmitoylation."
The discussion of the differences in the effects of palmitoylation of either Nde1 or Ndel1 and their association with dynein (p. 9) is confusing.
Modified, several additional sentences were added. "The difference between the behavior of Nde1 and Ndel1 in that respect may be due to slight differences in the sequence of the amino acids surrounding C273. In case of Ndel1 the amino acid in position 272 is alanine, which is an hydrophobic amino acid, whereas in case of Nde1 it is serine, which is an hydrophilic amino acid. Furthermore, the similarity between Ndel1 and Nde1 is markedly reduced after amino acid 277 (25.7% identity versus 54.4% identity along the whole protein). Amino acids in that region may also contribute to the interaction with dynein. Structural analysis of the complexes involving Nde1 or Ndel1 and dynein are likely to provide better insight into this issue." Fig. 4 
In the experiments in
, why does over-expression of DHHC7 not affect the regulation of the endogenous proteins?
We detected very low expression of Ndel1 and of the DHHC7 palmitoylation enzyme in NIH3T3 cells. This is demonstrated in a new supplementary figure (S4). A few sentences were added to the results "This hypothesis was tested directly by monitoring the activity of cytoplasmic dynein using several cellular assays using different cells. The levels of Ndel1 and the palmitoylation enzymes vary in the different cells (supplementary Fig. S4 ). Ndel1 is highly expressed in the brain and in CAD cells, it is expressed in moderate levels in NIH3T3 cells and very low levels in COS7 cells and HEK293 cells. DHHC7 expression is very low in NIH3T3 cells and HEK293 cells, and is better expressed in CAD, COS7, and brain lysate, whereas DHHC3 is expressed at high levels in NIH3T3 cells. Therefore, in some cases we needed to transfect both Ndel1 and the palmitoylation enzyme to observe an effect. " A corresponding legend and supplementary method was added as well.
Overall, this is nice work on a novel regulatory mechanism.
We thank the reviewer for the encouragement. Thank you for submitting your revised manuscript for our consideration. It has now been seen once more by the original referees 1 and 2. As you will see, both of them consider the manuscript improved in response to their original comments, and referee 1 is now in principle supportive of publication. On the other hand, it is however clear that referee 2 is at this point not fully satisfied, and still retains a number of major reservations.
Given these persistent problems and the fact that we normally allow for one round of major revision only, I further consulted with the Executive Editor of the journal, Dr. Pernille Rorth, who has now also taken a detailed look at the manuscript and the comments of the referees. As a conclusion from these in-depth considerations, we realize that you have clearly addressed many of the important points, including issues originally raised by referee 2. However, we also note that there remain a number of substantive concerns with the strong potential to undermine the main claims and conclusions if not satisfactorily clarified. This pertains especially to data shown in Figure 3 , where we have to agree with referee 2 that there is hardly a specific reduction in Ndel1 palmitoylation in the C273S mutant (Fig 3C) , putting into doubt the main functional experiments conducted with this presumably non-palmitoylated version; clearly more convincing would be essential as the fact that differences are observed upon DHHC 3 & 7 overexpression does not by itself appear to offer sufficiently definitive evidence for the conclusion that this site is normally palmitoylated/required for the protein to be palmytoylated. Moreover, there are also image quality issues here, concerning both panels 3E (where a repeat of the experiment might provide clearer data) and especially 3B, where bands from different blots appear to be spliced together into a final picture without indication nor justification. While I realize that these lanes may actually stem from the same exposure of the same blot/gel, and that the nature of the electronic manipulation may simply be a cosmetic issue to facilitate presentation, I have to nevertheless remind you that throughout such manipulations, a positive relationship between the original data and the resulting electronic image must always be maintained, and the nature and rationale of the manipulations made clear (please see our Guidelines for Authors, as well as Rossner and Yamada, JCB 166, 11-15, 2004 , on that issue). In said figure, all lanes are supposed to stem from the same experiment and exposure to allow the intended comparison to be made. In accordance with journal policy we would in this case need to see the original data accompanied by detailed explanations of the rationale behind the image processing in this panel, as well as a new version of this figure containing the data from a single experiment and clearly separating lanes from different parts -ideally by re-running these gels with the right order of lanes. Finally, we also noted that for Figure 7 , text and figure suggest that C273S Ndel1, but not Ndel1 expression cause migration problems, however the accompanying quantification does not substantiate this but implies effects of both wt and mutant Ndel1 -again this would need to be convincingly reconciled.
Despite these shortcomings, we would -given the overall interest of the findings -in this case exceptionally be willing to look once more at the study after a second round of major revision, if you feel confident that you might be able to completely -and convincingly -address these main problems, as well as the other points raised by referee 2. I should however make it clear that this will have to be the final round of revision for this manuscript, and that if the next version does not address these issues in a satisfactory manner, I am afraid we will have to reject the manuscript. In the revised version, the authors have made a considerable effort to address the concerns I had raised for the first version. In general, I feel that most of my criticism was addressed and the paper is close for publication. However, I still concern that how much Ndel1 palmitoylation contributes to dynein activation/inhibition. In fact, dynein is mobile without Ndel1 protein. It is understandable for technical difficulty for quantitation of palmitoylated Ndel1. One solution for this problem is discussion regarding other mechanism for dynein activation such as dynactin, and softening their description.
I also have two minor points which I think should be corrected before dissemination. This manuscript, improved by revision, makes a number of important contributions. First is the finding that the two homologous dynein regulatory subunits, Nde1 and Ndel1, are palmitoylated. Second, they identify Cys273 to be a key site required in both proteins for palmitoylation. Interestingly, the C273S mutation when introduced into the two paralogs associates with opposing phenotypes, suggesting both, differing functions of palmitoylation for the two proteins,and extrapolating further, that the two proteins may be functionally distinct, not functionally redundant as might have been expected from their extensive homology. Most of the subsequent work aims at the function of palmitoylation for Ndel1. Here, the weight of the evidence suggests that Ndel1 palmitoylation serves to negatively regulates dynein function. Finally, a series of in vivo in utero transfection experiments demonstrate striking effects on neuronal migration by transfected Ndel1-C273S and by constructs that more generally up-and down-regulate palmitoylation, through up-or down-regulation of the several DHHC PATs.
Obviously, this manuscript covers a lot of ground and perhaps it should not be surprising therefore, that numerous gaps remain to be filled. My comments below focus on what I perceive to be the most central deficiencies undermining confidence in the main conclusions. 1. The Ndel1 palmitoylation level in the different experiments. Newly added Fig. 1F suggests that endogenous Ndel1 is fully palmitoylated (complete DTT-mediated mobility shift). This result seems difficult to reconcile with the many experiments which find substantial effects of DHHC7 overproduction (e.g. Fig 3B, 3D , and 4). Are these effects truly exerted through increased Ndel1 palmitoylation? How can this be if Ndel1 in the absence of DHHC7 overproduction already is fully palmitoylated? Presumably, the authors' explanation would be that these experiments also involve Ndel1 overproduction and that overproduced Ndel1 is not fully palmitoylated unless DHHC7 also is overproduced. Such modulation of Ndel1 palmitoylation levels by DHHC7 overproduction should be directly demonstrated in the different experimental contexts using a mobility shift assay (hydroxylamine is preferred, see #2 below) or by monitoring Ndel1 palmitoylation directly by ABE or click.
2. DTT-induced mobility shift (Fig. 1F) . Conditions for this are not reported. Typically for this, very high DTT concentrations (e.g. 100 mM) are included in the pre SDS-PAGE boil. I am somewhat concerned therefore that this mobility shift might be an artifactual consequence of the substantial change in sample osmolarity. A somewhat more classical way of cleaving thioesters is with neutral pH hydroxylamine. This is something that the authors utilize in Fig 1C. Thus, the authors could easily test for a hydroxylamine-induced shift by blotting the Fig. 1C samples with anti-Ndel1.
3. Half-live of Ndel1 palmitoyl-modifications. Classically, to demonstrate palmitoylation turnover one shows that the rate of modification turnover exceeds the rate of protein turnover. What is the half-life of the Ndel1 protein in this experimental regimen? Rather than de-palmitoylation, it is conceivable that what is being followed in these two experiments is turnover of the protein itself. Also, the analysis by ABE (panel 1I) seems a bit funny in that the biggest effect of the 2BP treatment appears to be on Ndel1 protein amount, suggesting that the 2BP alters Ndel1 expression, either increasing synthesis or decreasing turnover. Certainly, the panel K quantification reflects, to some large extent, these changing Ndel1 protein levels, since the amount of Ndel1 protein detected figures into these calculations as the denominator.
4. Fig. 3C . 9. Fig. 3D . Duration and concentration of 2-BP treatment?
10. top of p12, typo. in a "pulse-chase" regimen, rather than: is a "pulse-chase" regimen.
11. bottom of p9. Rather than describing the sequence differences distinguishing Ndel1 from Nde1, it seems simpler and better to show a BLAST comparison of this portion of the two sequences, perhaps as part of Fig. 2 . We want to thank you for the opportunity to submit a new version of our manuscript. Please find below a detailed letter addressing the comments provided by the editors and the referees. We believe that we have modified our manuscript in a significant way and hope that in its current form will be accepted for publication in EMBO Journal. For Figure 3B we prepared a figure detailing the manipulations done. On the top we show the original blots, and show which lanes we decided to remove, and on the bottom the final results. We modified Figure 3B by adding a dashed line to indicate the positions where the figure was cut. We repeated the experiments of Figure 3E several times. We now show in Figure 3E the best images we obtained. Still, for an unknown reason, DIC appears somewhat as a smeary band. The repetitions of this experiment allowed us to quantify and statistically analyze the differences in the binding of Nde1 and DIC. We added these results in the main text "Nevertheless, cysteine 273 plays an important role in mediating the binding of Nde1 to cytoplasmic dynein, as Nde1 C273S exhibited a 5.6 fold reduced interaction with DIC (paired Student t test p=0.0004) regardless of the presence of the palmitoylation enzyme (Fig. 3E) . "
" Finally, we also noted that for Figure 7 , text and figure suggest that C273S Ndel1, but not Ndel1 expression cause migration problems, however the accompanying quantification does not substantiate this but implies effects of both wt and mutant Ndel1 -again this would need to be convincingly reconciled.
The statistical analysis did not indicate significant differences. To address this issue, we repeated the experiment and added additional brain sections to the statistical analysis. The addition resulted in a statistically significant difference between wt Ndel1 and the control that was previously lacking. The histogram was replaced and the text was modified accordingly. "Expression of Ndel1, which activates cytoplasmic dynein inhibited neuronal migration (Fig. 7B,G We added a sentence to the discussion "Furthermore, dyenin is regulated by interacting proteins such as dynactin (reviews (Schroer, 2004; Vallee et al, 2004) We thank the reviewer and have modified the abovementioned comments.
Reviewer #2 We thank the reviewer for his comments and addressed each of the, as detailed below.
The Ndel1 palmitoylation level in the different experiments. Newly added Fig. 1F suggests that endogenous Ndel1 is fully palmitoylated (complete DTT-mediated mobility shift)
. This result seems difficult to reconcile with the many experiments which find substantial effects of DHHC7 overproduction (e.g. Fig 3B, 3D, We monitored Ndel1 palmitoylation in HEK293 cells and in COS7 cells using the different combinations we used in other experiments by radioactive palmitate. These results are presented in supplementary figure S6 . The transfection efficiency in NIH3T3 cells is too low for such biochemical assays. In CAD cells, we did not need to cotransfect Ndel1 and the enzyme and the endogenous palmitoylation is observed by band shift using hydroxlamide (detailed below). (Fig. 1F) The experiments were repeated using hydroxylamine. Modified text "It has been previously demonstrated that a band-shift of PSD95 can be noted following addition of hydroxylamine ( (Fukata et al, 2004) , Fig. 1E ). We noted a similar band-shift of Ndel1 (Fig. 1F) , thus suggesting that a noticeable proportion of Ndel1 population is palmitoylated in CAD cells." Modified legend to figure "E-F) A band shift is noted when PSD95 from brain lysate (E) or Ndel1 from CAD cell lysate (F) are separated on SDS-PAGE following addition of neutral pH hydroxylamine (without HA -, with HA +,). Short arrows indicate the position of the nontreated bands while the longer arrows indicate the positions of the hydroxylamine treated bands." This experiment is included in Fig. 1 H, the experimental details were added to the supplementary data. Main text addition: "The half-life of Ndel1 palmitoylation was estimated to be 1.75 hrs (R2=0.985). Ndel1 is a very stable protein and the protein half-life was estimated to be 24 hrs ( Fig. 1H and supplementary data)." Legend to figure modification: "H) Palmitoylation and protein half-life linear regression. The in gel fluorescence intensity was normalized according to the amount of immunoprecipiated Ndel1 and plotted (data points are triangles and the linear regression is solid black line). Ndel1 protein half-life data (described in supplementary methods) was ploted as well (data points are squares ±SEM and the linear regression is a dashed line). Ndel1 is a very stable protein with an estimated half-life of about 24 hrs, Ndel1 palmitoylation half-life is about 1.7 hrs." Addition to supplementary data: "Protein half-life Cultured HEK-293 cells were transiently transfected with MYC-tagged Ndel1 or FLAGtagged p21 (a protein with a known short-life). Fourty-eight hours after transfection, cells were treated with 25 g/ml of cycloheximide (Sigma), in time intervals of 1 hour. The maximal treatment was for five hours. Control cells were not treated with cycloheximide. The cells were harvested and cell lysates were collected. Equal amount of proteins were separated by SDS-PAGE and subjected to Western blot analysis using anti-MYC, anti-FLAG or DM1a (anti-alpha tubulin) antibodies. Results were quantified using the "ImageJ" software. The amount of protein was normalized according to tubulin reactivity and the data was plotted and subjected to linear regression analysis using GraphPad Prism computation program version 4.0 for Macintosh. The calculated half-life of p21 was calculated to 2.5 hrs, which fits well with published data (Stuart & Wang, 2009 
DTT-induced mobility shift
